Collectively these data indicate that activation of AKT/mTOR pathway is involved in BRCA1-deficiency mediated tumorigenesis and that the inhibition of AKT/mTOR pathway can be used as a target for treatment of BRCA1-deficient breast cancers. This evidence concerns the gene MTOR and breast cancer.